Thomas Zachariah, Fraser Gilles L
Ernest Mario School of Pharmacy-Rutgers, State University of New Jersey, Piscataway, NJ, USA.
Ann Pharmacother. 2007 Sep;41(9):1456-65. doi: 10.1345/aph.1K082. Epub 2007 Aug 14.
To examine recent literature regarding corticotherapy in critically ill patients suffering from sepsis, acute respiratory distress syndrome (ARDS), and severe community-acquired pneumonia (SCAP).
Literature was identified through MEDLINE (1966-April 2007) using combinations of the key words hydrocortisone, adrenal insufficiency, acute respiratory distress syndrome, pneumonia, sepsis, and cortisol. Bibliographies of relevant articles were reviewed for additional citations. Presentations at recent critical care meetings were also incorporated.
Articles were chosen based upon their relevance to the topics covered.
Earlier studies using high-dose corticotherapy in the intensive care unit have shown treatment to be ineffective. Recent studies using extended courses of low-to-moderate doses of steroids have found favorable results; however, these results must be interpreted with caution due to limitations in the data. One trial of steroids in septic shock found a survival benefit in patients who failed to increase their baseline cortisol by greater than 9 microg/dL in response to adrenocorticotropic hormone, but these results were not reproduced in a subsequent Phase 3 trial. Recently, inaccuracies in measuring cortisol have been identified, making interpretation of cortisol concentrations difficult. A large-scale study failed to confirm a previously reported mortality benefit of corticotherapy in late ARDS, but preliminary data suggest a role for steroid treatment in early ARDS. Finally, a pilot study has found that hydrocortisone lowers morbidity and mortality in SCAP.
Corticotherapy may be beneficial to some patients with sepsis. The decision to administer steroids in sepsis cannot be based on biochemical markers of adrenal function; rather, treatment should be considered in septic patients with vasopressor refractory hypotension. Although preliminary evidence suggests a role for steroids in early ARDS and SCAP, there are not enough data to suggest routine administration of steroids in these conditions. Additional studies are needed to assess corticotherapy in the critically ill.
研究近期关于皮质激素疗法用于脓毒症、急性呼吸窘迫综合征(ARDS)及重症社区获得性肺炎(SCAP)重症患者的文献。
通过MEDLINE(1966年至2007年4月)检索文献,使用关键词氢化可的松、肾上腺功能不全、急性呼吸窘迫综合征、肺炎、脓毒症和皮质醇的组合。查阅相关文章的参考文献以获取更多引用文献。近期危重症会议的报告也纳入其中。
根据文章与所涵盖主题的相关性进行选择。
早期在重症监护病房使用大剂量皮质激素疗法的研究显示治疗无效。近期使用低至中等剂量类固醇延长疗程的研究取得了良好结果;然而,由于数据存在局限性,这些结果必须谨慎解读。一项关于脓毒性休克中类固醇的试验发现,对促肾上腺皮质激素反应时基线皮质醇升高未超过9微克/分升的患者有生存获益,但这些结果在随后的3期试验中未得到重现。最近,已发现皮质醇测量存在不准确之处,使得皮质醇浓度的解读变得困难。一项大规模研究未能证实先前报道的皮质激素疗法对晚期ARDS的死亡率益处,但初步数据表明类固醇治疗在早期ARDS中可能起作用。最后,一项初步研究发现氢化可的松可降低SCAP的发病率和死亡率。
皮质激素疗法可能对一些脓毒症患者有益。脓毒症中使用类固醇的决定不能基于肾上腺功能的生化指标;相反,对于血管升压药难治性低血压的脓毒症患者应考虑进行治疗。尽管初步证据表明类固醇在早期ARDS和SCAP中可能起作用,但尚无足够数据支持在这些情况下常规使用类固醇。需要更多研究来评估重症患者的皮质激素疗法。